immersiv HEALTH

STELARA® IV ORDER FORM

FAX TO: 855.694.4656

PATIENT INFORMATION

PATIENT NAME: _____ **PHONE:** _____

DATE OF BIRTH: _____ **SEX:** ☐ M ☐ F **HEIGHT:** _____ **WEIGHT:** _____ ☐ LBS ☐ KG

ALLERGIES: _____ **PREFERRED CLINIC:** _____

REFERRAL STATUS: ☐ NEW REFERRAL ☐ ORDER CHANGE ☐ ORDER RENEWAL

DIAGNOSIS & CLINICAL DOCUMENTATION

☐	K50.00 Crohn's Disease – small intestine	☐	K51.00 Universal Ulcerative Pancolitis – chronic
☐	K50.10 Crohn's Disease – large intestine	☐	K51.50 Left sided Ulcerative Colitis – chronic
☐	K50.80 Crohn's Disease – small & large intestine	☐	K51.80 Other Ulcerative Colitis – chronic
☐	K50.90 Crohn's Disease, unspecified	☐	K51.90 Ulcerative Colitis

☐ ICD-10 CODE: _____ DESCRIPTION: _____

REQUIRED DOCUMENTATION

☐ Insurance Information ☐ List of Medications ☐ Tried & Failed Therapies ☐ Most Recent History & Physical ☐ Negative TB Screening

MEDICATION ORDER

For Patients Weighing < 55 kg

☐ **INDUCTION:** Stelara® (ustekinumab) 260 mg IV in 250 ml NS over 60 minutes

For Patients Weighing 55 kg to 85 kg

☐ **INDUCTION:** Stelara® (ustekinumab) 390 mg IV in 250 ml NS over 60 minutes

For Patients Weighing > 85 kg

☐ **INDUCTION:** Stelara® (ustekinumab) 520 mg IV in 250 ml NS over 60 minutes

☐ **OTHER:** _____

*Referring provider to coordinate Sub-Q maintenance dosing with appropriate specialty pharmacy

PRE-MEDICATIONS

PO

☐ Acetaminophen: 650 mg
☐ Cetirizine: 10 mg
☐ Diphenhydramine: 25 mg

IV

☐ Methylprednisolone: 125 mg
☐ Diphenhydramine: 25 mg

☐ **OTHER:** _____ ☐ PO ☐ IV

Patient to be observed for 30 minutes following the first infusion.
In the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health adverse reaction protocol.

PRESCRIBER INFORMATION

PROVIDER NAME: _____ **NPI #:** _____

EMAIL: _____ **PHONE:** _____ **FAX:** _____

ADDRESS (INCLUDE CITY, STATE, ZIP): _____

SUPERVISING PHYSICIAN: (IF APPLICABLE) _____ **CONTACT NAME:** _____

SIGNATURE: (NO STAMPS) _____ _____ **DATE:** _____

SUBSTITUTION PERMITTED DISPENSE AS WRITTEN